

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>	Attorney Docket No.	240636US0X
	First Inventor or Application Identifier	Alexander B. MAURER
	Title	NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS
Assignee Name:		1) 4SC AG 2) G2M Cancer Drugs AG
Assignee Address:		1) Am Klopferplatz 19a 82152 Martinsried, GERMANY 2) Georg-Speyer Haus, Paul-Ehrlich-Strasse 42-44, 60596 Frankfurt/Main, GERMANY

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents</small>	<b>ADDRESS TO:</b> Commissioner for Patents Mail Stop Patent Application Alexandria, Virginia 22313
1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g. PTO/SB/17) <small>(Submit an original and a duplicate for fee processing)</small>  2. <input checked="" type="checkbox"/> Specification Total Sheets <span style="border: 1px solid black; padding: 0 10px;">29</span>  3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) Total Sheets <span style="border: 1px solid black; padding: 0 10px;">7</span>  4. <input type="checkbox"/> Oath or Declaration Total Pages <span style="border: 1px solid black; padding: 0 10px;"></span> <div style="margin-left: 20px;">           a. <input type="checkbox"/> Newly executed (original or copy)            b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. §1.63(d))  <small>(for continuation/divisional with box 17 completed)</small>            i. <input type="checkbox"/> DELETION OF INVENTOR(S)  <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §1.63(d)(2) and 1.33(b).</small>            5. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)            6. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)            a. <input type="checkbox"/> Computer Readable Form (CRF)            b. Specification or Sequence Listing on :               i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or               ii. <input type="checkbox"/> Paper            c. <input type="checkbox"/> Statements verifying identity of above copies         </div>	<b>ACCOMPANYING APPLICATION PARTS</b>  7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 8. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 9. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small> 10. <input type="checkbox"/> English Translation Document (if applicable) 11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 12. <input checked="" type="checkbox"/> Preliminary Amendment 13. <input checked="" type="checkbox"/> White Advance Serial No. Postcard 14. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 15. <input type="checkbox"/> Applicant claims small entity status. <small>See 37 CFR 1.27</small> 16. <input type="checkbox"/> Other:

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application no.:  
 Prior application information: Examiner: Group Art Unit:

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. Amend the specification by inserting before the first line the sentence:

☐ This application is a ☐ Continuation ☐ Division ☐ Continuation-in-part (CIP)  
 of application Serial No. Filed on

☒ This application claims priority of provisional application Serial No. 60/397,663 Filed July 23, 2002

**19. CORRESPONDENCE ADDRESS**

  
**22850**  
 (703) 413-3000  
 FACSIMILE: (703) 413-2220

Name:	Norman F. Oblon	Registration No.:	24,618
Signature:	<i>FO Vastine</i>	Date:	7/23/03
Name:	Frederick D. Vastine, Ph.D.	Registration No.:	27,013

Docket No. 240636US0X

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

INVENTOR(S) Alexander B. MAURER, et al.

SERIAL NO: New Application

FILING DATE: Herewith

FOR: NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS

**FEE TRANSMITTAL**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	16 - 20 =	0	x \$18 =	\$0.00
INDEPENDENT CLAIMS	1 - 3 =	0	x \$84 =	\$0.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS (If applicable)			+ \$280 =	\$0.00
<input checked="" type="checkbox"/> LATE FILING OF DECLARATION			+ \$130 =	\$130.00
			BASIC FEE	\$750.00
TOTAL OF ABOVE CALCULATIONS				\$880.00
<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY				\$0.00
<input type="checkbox"/> FILING IN NON-ENGLISH LANGUAGE			+ \$130 =	\$0.00
<input type="checkbox"/> RECORDATION OF ASSIGNMENT			+ \$40 =	\$0.00
TOTAL				\$880.00

- ☐ Please charge Deposit Account No. 15-0030 in the amount of A duplicate copy of this sheet is enclosed.
- ☒ A check in the amount of **\$880.00** to cover the filing fee is enclosed.
- ☒ The Director is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

*FD Vastine*

Norman F. Oblon

Registration No. 24,618

Date: 7/23/03



**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 03/03)

Frederick D. Vastine, Ph.D.

Registration No. 27,013